×
验证码:
换一张
Forgotten Password?
Stay signed in
×
Log In By Account
English
|
Traditional Chinese
|
Simplified Chinese
Log In By Account
Register
ALL
ORCID
Title
Creator
Date Issued
Subject Area
Keyword
Document Type
Source Publication
Date Accessioned
Indexed By
Publisher
Funding Project
MOST Discipline Catalogue
Study Hall
Image search
Paste the image URL
Home
Collections
Authors
DocType
Subjects
K-Map
Evaluation
K-Integration
Study Hall
News
Search in the results
Collection
Institute ... [4]
Faculty of... [3]
Authors
LU JINJIAN [3]
TAM KIN YI... [2]
CHEN XIUPI... [2]
WANG YITAO [1]
KWOK HANG ... [1]
CHEN MEIWA... [1]
More...
Document Type
Journal ar... [8]
Date Issued
2018 [4]
2017 [2]
2014 [1]
2013 [1]
Language
英语 [7]
Source Publication
EUROPEAN J... [2]
ACTA PHARM... [1]
Anti-Cance... [1]
CANCER LET... [1]
Cancer Let... [1]
INTERNATIO... [1]
More...
Funding Project
Indexed By
SCI [8]
Funding Organization
×
Knowledge Map
UM
Start a Submission
Submissions
Unclaimed
Claimed
Attach Fulltext
Bookmarks
Browse/Search Results:
1-8 of 8
Help
Selected(
0
)
Clear
Items/Page:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Sort:
Select
Author Ascending
Author Descending
Title Ascending
Title Descending
Submit date Ascending
Submit date Descending
WOS Cited Times Ascending
WOS Cited Times Descending
Journal Impact Factor Ascending
Journal Impact Factor Descending
Issue Date Ascending
Issue Date Descending
Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer
Journal article
EUROPEAN JOURNAL OF PHARMACOLOGY, 2018,Volume: 838,Page: 41-52
Authors:
Yang, Zheng
;
Zhang, Shao-Lin
;
Hu, Xiaohui
;
Tam, Kin Yip
Favorite
  |  
View/Download:12/0
  |  
Submit date:2018/10/30
Dichloroacetophenone
Epidermal growth factor receptor
Tyrosine kinase inhibitor
Synergism
Hypoxia
Oxidative phosphorylation
Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes
Journal article
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2018,Volume: 14,Issue: 2,Page: 204-216
Authors:
Yang, Zheng
;
Tam, Kin Yip
Favorite
  |  
View/Download:12/0
  |  
Submit date:2018/10/30
Combination
Egfr-tki
Nsclc
Chemotherapy
Targeted Therapy
Immunotherapy
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
Journal article
CANCER LETTERS, 2018,Volume: 420,Page: 242-246
Authors:
Tang, Zheng-Hai
;
Lu, Jin-Jian
Favorite
  |  
View/Download:9/0
  |  
Submit date:2018/10/30
Osimertinib
Azd9291
Egfr Tki
Resistant Mechanisms
Therapeutic Strategies
Increased expression of IRE1α associates with the resistant mechanism of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells
Journal article
Anti-Cancer Agents in Medicinal Chemistry, 2018,Volume: 18,Issue: 4,Page: 550-555
Authors:
Tang Z.-H.
;
Su M.-X.
;
Guo X.
;
Jiang X.-M.
;
Jia L.
;
Chen X.
;
Lu J.-J.
Favorite
  |  
View/Download:3/0
  |  
Submit date:2018/12/28
Azd9291
Egfr
Ire1α
Lune Cancer
Nsclc
Osimertinib
Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells
Journal article
EUROPEAN JOURNAL OF PHARMACOLOGY, 2017,Volume: 815,Page: 80-87
Authors:
Yang, Zheng
;
Hu, Xiaohui
;
Zhang, Shaolin
;
Zhang, Wen
;
Tam, Kin Yip
Favorite
  |  
View/Download:19/0
  |  
Submit date:2018/10/30
Synergism
Dichloroacetophenone
Dichloroacetate
Egfr
Apoptosis
Acquired Resistance
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells
Journal article
ACTA PHARMACOLOGICA SINICA, 2017,Volume: 38,Issue: 11,Page: 1512-1520
Authors:
Jiang, Xiao-Ming
;
Xu, Yu-Lian
;
Huang, Mu-Yang
;
Zhang, Le-Le
;
Su, Min-Xia
;
Chen, Xiuping
;
Lu, Jin-Jian
Favorite
  |  
View/Download:15/0
  |  
Submit date:2018/10/30
Non-small Cell Lung Cancer
Egfr
Osimertinib
Pd-l1
Ubiquitin-proteasome System
Mg-132
Bortezomib
Gsk3 Beta
Licl
Targeting the sheddase activity of Adam17 by an Anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation
Journal article
International Journal of Biological Sciences, 2014,Volume: 10,Issue: 7,Page: 702-714
Authors:
Huang Y.
;
Benaich N.
;
Tape C.
;
Kwok H.F.
;
Murphy G.
Favorite
  |  
View/Download:4/0
  |  
Submit date:2018/12/19
Adam17
Cell Proliferation And Motility
Her Receptor And ligAnds
Inhibitory Antibody
IC-4, a new irreversible EGFR inhibitor, exhibits prominent anti-tumor and anti-angiogenesis activities
Journal article
Cancer Letters, 2013,Volume: 340,Issue: 1,Page: 88
Authors:
Li Y.-B.
;
Wang Z.-Q.
;
Yan X.
;
Chen M.-W.
;
Bao J.-L.
;
Wu G.-S.
;
Ge Z.-M.
;
Zhou D.-M.
;
Wang Y.-T.
;
Li R.-T.
Favorite
  |  
View/Download:3/0
  |  
Submit date:2018/10/31
Angiogenesis
Breast Cancer
Egfr
Irreversible Tki